This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Niemeier, A. Articles by Beisiegel, U. Search for Related Content PubMed PubMed Citation Articles by Niemeier, A. Articles by Beisiegel, U. Related Collections Gene expression Genetically altered mice Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:552-561.)
© 1999 American Heart Association, Inc.

Original Contributions

Identification of Megalin/gp330 as a Receptor for Lipoprotein(a) In Vitro

Andreas Niemeier; Thomas Willnow; Hans Dieplinger; Christian Jacobsen; Nicolette Meyer; Jan Hilpert; Ulrike Beisiegel
Abstract—Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein of unknown physiological function. The mechanism of Lp(a) atherogenicity as well as its catabolic pathways are only incompletely understood at present. In this report, we show that the low density lipoprotein receptor (LDLR) gene family member megalin/glycoprotein (gp) 330 is capable of binding and mediating the cellular uptake and degradation of Lp(a) in vitro. A mouse embryonic yolk sac cell line with native expression of megalin/gp330 but genetically deficient in LDLR-related protein (LRP) and a control cell line carrying a double knockout for both LRP and megalin/gp330 were compared with regard to their ability to bind, internalize, and degrade dioctadecyltetramethylindocarbocyanine perchlorate (DiI)-fluorescence–labeled Lp(a) as well as equimolar amounts of ¹²⁵I-labeled Lp(a) and LDL. Uptake and degradation of radiolabeled Lp(a) by the megalin/gp330-expressing cells were, on average, 2-fold higher than that of control cells. This difference could be completely abolished by addition of the receptor-associated protein, an inhibitor of ligand binding to megalin/gp330. Mutual suppression of the uptake of ¹²⁵I-Lp(a) and of ¹²⁵I-LDL by both unlabeled Lp(a) and LDL suggested that Lp(a) uptake is mediated at least partially by apolipoprotein B100. Binding and uptake of DiI-Lp(a) resulted in strong signals on megalin/gp330-expressing cells versus background only on control cells. In addition, we show that purified megalin/gp330, immobilized on a sensor chip, directly binds Lp(a) in a Ca²⁺-dependent manner with an affinity similar to that for LDL. We conclude that megalin/gp330 binds Lp(a) in vitro and is capable of mediating its cellular uptake and degradation.

Key Words: megalin • glycoprotein 330 • lipoprotein(a) • LDL • LDLR gene family

This article has been cited by other articles:

				G. Pepe, G. Chimienti, G. M. Liuzzi, B. L. Lamanuzzi, M. Nardulli, F. Lolli, E. Angles-Cano, and S. Mata Lipoprotein(a) in the Cerebrospinal Fluid of Neurological Patients with Blood-Cerebrospinal Fluid Barrier Dysfunction Clin. Chem., November 1, 2006; 52(11): 2043 - 2048. [Abstract] [Full Text] [PDF]

				W. J. Cain, J. S. Millar, A. S. Himebauch, U. J. F. Tietge, C. Maugeais, D. Usher, and D. J. Rader Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a] J. Lipid Res., December 1, 2005; 46(12): 2681 - 2691. [Abstract] [Full Text] [PDF]

				J. Fan, M. Challah, H. Shimoyamada, M. Shiomi, S. Marcovina, and T. Watanabe Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein[a] J. Lipid Res., June 1, 2000; 41(6): 1004 - 1012. [Abstract] [Full Text]

				B. Garner, A. H. Merry, L. Royle, D. J. Harvey, P. M. Rudd, and J. Thillet Structural Elucidation of the N- and O-Glycans of Human Apolipoprotein(a). ROLE OF O-GLYCANS IN CONFERRING PROTEASE RESISTANCE J. Biol. Chem., June 15, 2001; 276(25): 22200 - 22208. [Abstract] [Full Text] [PDF]